Cardiovascular Systems, Inc. (NASDAQ:CSII) Files An 8-K Other EventsItem 8.01. Other Events.
On March 23, 2018, the independent members of the Board of Directors of Cardiovascular Systems, Inc. (the “Company”) approved a waiver of the conflict of interest provisions of the Company’s Code of Ethics and Business Conduct with respect to the provision of certain laboratory support services to TVA Medical, Inc. (“TVA”) by the Company. Dr. William Cohn, a member of the Company’s Board of Directors, is also a director and stockholder of TVA, a development stage company. TVA will pay CSI fair market value rates for these services, which are expected to be less than $12,000 in the aggregate. Dr. Cohn and Scott Ward, the Company’s Chairman, Chief Executive Officer and President, did not participate in such vote. Dr. Cohn will recuse himself on both the Company and TVA boards with respect to any issues that involve both the Company and TVA.
About Cardiovascular Systems, Inc. (NASDAQ:CSII)
Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company’s coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.
